Therapeutic roles of thiazides and loop diuretics in blood pressure control and renal protection against chronic kidney disease

키워드

참고문헌 (76)

1. Camafort Miguel, "Intensive blood pressure lowering: a practical review", Clinical Hypertension, 26(4), pp.28~35 (2020), 대한고혈압학회[DOI]
2. Oh Kook-Hwan, "The KNOW-CKD Study: What we have learned about chronic kidney diseases", Kidney Research and Clinical Practice, 39(2), pp.121~135 (2020), 대한신장학회[DOI]
3. 이해경, "Association between blood pressure and the risk of chronic kidney disease in treatment-naïve hypertensive patients", Kidney Research and Clinical Practice, 41(1), pp.31~42 (2022), 대한신장학회[DOI]
4. 신진호, "The roles of sodium and volume overload on hypertension in chronic kidney disease", Kidney Research and Clinical Practice, 40(4), pp.542~554 (2021), 대한신장학회[DOI]
5. Baki Aber Halim, "Are there any further modalities for prediction of subclinical volume overload in advanced stages of chronic kidney disease?", Kidney Research and Clinical Practice, 40(1), pp.143~152 (2021), 대한신장학회[DOI]
6. Adriaan Slabbert, "The association between office blood pressure and fluid status using bioimpedance spectroscopy in stable continuous ambulatory peritoneal dialysis patients", Clinical Hypertension, 28, pp.8~8 (2022), 대한고혈압학회[DOI]
7. Kidney Disease. Improving global outcomes (KDIGO) blood pressure Work Group, "KDIGO 2021 Clinical Practice Guideline for the management of blood pressure in chronic kidney disease", Kidney Int, 99(3S), pp.1~87 (2021)
8. Agarwal R, "Chlorthalidone for hypertension in advanced chronic kidney disease", N Engl J Med, 385, pp.2507~2519 (2021)
9. Polychronopoulou E, "How do I manage hypertension in patients with advanced chronic kidney disease not on dialysis?: perspectives from clinical practice", Vasc Health Risk Manag, 17, pp.1~11 (2021)
10. Cheung AK, "Effects of intensive BP control in CKD", J Am Soc Nephrol, 28, pp.2812~2823 (2017)
11. ACCORD Study Group, "Effects of intensive blood-pressure control in type 2 diabetes mellitus", N Engl J Med, 362, pp.1575~1585 (2010)
12. SPRINT Research Group, "A randomized trial of intensive versus standard blood-pressure control", N Engl J Med, 373, pp.2103~2116 (2015)
13. Wheeler DC, "Chlorthalidone in advanced chronic kidney disease : have we missed a trick?", N Engl J Med, 385, pp.2574~2575 (2021)
14. Dasgupta I, "Is the KDIGO systolic blood pressure target < 120 mm hg for chronic kidney disease appropriate in routine clinical practice?", Hypertension, 79, pp.4~11 (2022)
15. Weber MA, "Clinical practice guidelines for the management of hypertension in the community : a statement by the American Society of Hypertension and the International Society of Hypertension", J Clin Hypertens(Greenwich), 16, pp.14~26 (2014)
16. Whelton PK, "ACC", AHA, ABC, pp.ACPM, AGS[DOI]
17. Canbakan B, "Rational approaches to the treatment of hypertension : drug therapy-monotherapy, combination, or fixed-dose combination?", Kidney Int Suppl(2011), 3, pp.349~351 (2013)
18. Riya Tejas Shah, "Effectiveness of renal denervation in the treatment of hypertension: a literature review", Clinical Hypertension, 28, pp.11~11 (2022), 대한고혈압학회[DOI]
19. Guyton AC, "Kidneys and fluids in pressure regulation. Small volume but large pressure changes", Hypertension, 19(1 Suppl), pp.I2~I8 (1992)
20. Guyton AC, "Blood pressure control : special role of the kidneys and body fluids", Science, 252, pp.1813~1816 (1991)
21. Hung SC, "Volume overload and adverse outcomes in chronic kidney disease : clinical observational and animal studies", J Am Heart Assoc, 4, pp.e001918~ (2015)
22. De Nicola L, "Achievement of target blood pressure levels in chronic kidney disease : a salty question?", Am J Kidney Dis, 43, pp.782~795 (2004)
23. Seldin DW, "Regulation of proximal reabsorption by effective arterial blood volume", Semin Nephrol, 11, pp.212~219 (1991)
24. Kim Hyeon Chang, "Korea hypertension fact sheet 2021: analysis of nationwide population-based data with special focus on hypertension in women", Clinical Hypertension, 28, pp.1~1 (2022), 대한고혈압학회[DOI]
25. Liu Jing, "Highlights of the 2018 Chinese hypertension guidelines", Clinical Hypertension, 26(3), pp.20~25 (2020), 대한고혈압학회[DOI]
26. James PA, "2014 evidence-based guideline for the management of high blood pressure in adults : report from the panel members appointed to the Eighth Joint National Committee(JNC 8)", JAMA, 311, pp.507~520 (2014)
27. Wright JT Jr, "Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease : results from the AASK trial", JAMA, 288, pp.2421~2431 (2002)
28. Jamerson K, "Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients", N Engl J Med, 359, pp.2417~2428 (2008)
29. Bakris GL, "Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events(ACCOMPLISH) : a prespecified secondary analysis of a randomised controlled trial", Lancet, 375, pp.1173~1181 (2010)
30. ALLHAT Officers, "The antihypertensive and lipid-lowering treatment to Prevent Heart Attack Trial : major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic : the antihypertensive and lipid-lowering treatment to Prevent Heart Attack Trial(ALLHAT)", JAMA, 288, pp.2981~2997 (2002)
31. Barzilay JI, "Longterm effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension : the ALLHAT Diabetes Extension Study", Circ Cardiovasc Qual Outcomes, 5, pp.153~162 (2012)
32. Liang W, "Comparison of thiazide-like diuretics versus thiazide-type diuretics : a meta-analysis", J Cell Mol Med, 21, pp.2634~2642 (2017)
33. Chobanian AV, "The seventh report of the Joint National Committee on Prevention, detection, evaluation, and treatment of high blood pressure : the JNC 7 report", JAMA, 289, pp.2560~2572 (2003)
34. Kidney Disease Outcomes Quality Initiative(K, "DOQI)", K, Am J Kidney Dis, pp.2004, 43(5 Suppl 1)[DOI]
35. Agarwal R, "Chlorthalidone for poorly controlled hypertension in chronic kidney disease : an interventional pilot study", Am J Nephrol, 39, pp.171~182 (2014)
36. Sinnakirouchenan R, "Role of sodium restriction and diuretic therapy for"resistant"hypertension in chronic kidney disease", Semin Nephrol, 34, pp.514~519 (2014)
37. Blowey DL, "Diuretics in the treatment of hypertension", Pediatr Nephrol, 31, pp.2223~2233 (2016)
38. Sinha AD, "Clinical pharmacology of antihypertensive therapy for the treatment of hypertension in CKD", Clin J Am Soc Nephrol, 14, pp.757~764 (2019)
39. Ishani A, "Chlorthalidone vs. hydrochlorothiazide for hypertension-cardiovascular events", N Engl J Med, 387, pp.2401~2410 (2022)
40. Hripcsak G, "Comparison of cardiovascular and safety outcomes of chlorthalidone vs hydrochlorothiazide to treat hypertension", JAMA Intern Med, 180, pp.542~551 (2020)
41. Edwards C, "Comparison of clinical outcomes and safety associated with chlorthalidone vs hydrochlorothiazide in older adults with varying levels of kidney function", JAMA Netw Open, 4, pp.e2123365~ (2021)
42. Risso MA, "The importance of tubular function in chronic kidney disease", Int J Nephrol Renovasc Dis, 12, pp.257~262 (2019)
43. Duarte JD, "Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics", Expert Rev Cardiovasc Ther, 8, pp.793~802 (2010)
44. Solomon RJ, "Thiazide induced hypotension : the role of plasma volume reduction and the urinary kallikrein system", Adv Exp Med Biol, 198, pp.243~251 (1986)
45. Bennett WM, "Do diuretics have antihypertensive properties independent of natriuresis?", Clin Pharmacol Ther, 22(5 Pt 1), pp.499~504 (1977)
46. Huang X, "Everything we always wanted to know about furosemide but were afraid to ask", Am J Physiol Renal Physiol, 310, pp.F958~F971 (2016)
47. Castrop H, "Isoforms of renal Na-K-2Cl cotransporter NKCC2 : expression and functional significance", Am J Physiol Renal Physiol, 295, pp.F859~66 (2008)
48. Schnermann J, "Tubular control of renin synthesis and secretion", Pflugers Arch, 465, pp.39~51 (2013)
49. Gehr TW, "The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency", Clin Pharmacol Ther, 56, pp.31~38 (1994)
50. Vasavada N, "A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease", Kidney Int, 64, pp.632~640 (2003)
51. Brater DC, "Diuretic therapy", N Engl J Med, 339, pp.387~395 (1998)
52. Abraham B, "Meta-analysis comparing torsemide versus furosemide in patients with heart failure", Am J Cardiol, 125, pp.92~99 (2020)
53. Dussol B, "A pilot study comparing furosemide and hydrochlorothiazide in patients with hypertension and stage 4 or 5 chronic kidney disease", J Clin Hypertens(Greenwich), 14, pp.32~37 (2012)
54. Levey AS, "Nomenclature for kidney function and disease : executive summary and glossary from a Kidney Disease : Improving Global Outcomes consensus conference", Nephrol Dial Transplant, 35, pp.1077~1084 (2020)
55. Hayashi SY, "Acute effects of low and high intravenous doses of furosemide on myocardial function in anuric haemodialysis patients : a tissue Doppler study", Nephrol Dial Transplant, 23, pp.1355~1361 (2008)
56. Gosmanova EO, "Association of systolic blood pressure variability with mortality, coronary heart disease, stroke, and renal disease", J Am Coll Cardiol, 68, pp.1375~1386 (2016)
57. Kostis JB, "Visit-to-visit blood pressure variability and cardiovascular death in the systolic hypertension in the Elderly Program", J Clin Hypertens(Greenwich), 16, pp.34~40 (2014)
58. Chang TI, "Visit-to-visit variability of blood pressure and death, end-stage renal disease, and cardiovascular events in patients with chronic kidney disease", J Hypertens, 34, pp.244~252 (2016)
59. Gregg LP, "Association of blood pressure variability and diuretics with cardiovascular events in patients with chronic kidney disease stages 1–5", Hypertension, 77, pp.948~959 (2021)
60. Trujillo H, "The forgotten antiproteinuric properties of diuretics", Am J Nephrol, 52, pp.435~449 (2021)
61. Buter H, "The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide", Nephrol Dial Transplant, 13, pp.1682~1685 (1998)
62. Uzu T, "Thiazide diuretics enhance nocturnal blood pressure fall and reduce proteinuria in immunoglobulin a nephropathy treated with angiotensin II modulators", J Hypertens, 23, pp.861~865 (2005)
63. Vogt L, "Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan", J Am Soc Nephrol, 19, pp.999~1007 (2008)
64. Kwakernaak AJ, "Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy : a randomised clinical trial", Lancet Diabetes Endocrinol, 2, pp.385~395 (2014)
65. Hoshino T, "Renoprotective effects of thiazides combined with loop diuretics in patients with type 2diabetic kidney disease", Clin Exp Nephrol, 19, pp.247~253 (2015)
66. Marre M, "Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes : the NESTOR Study", J Hypertens, 22, pp.1613~1622 (2004)
67. Esnault VL, "Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents", J Am Soc Nephrol, 16, pp.474~481 (2005)
68. Esnault VL, "Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration", Nephrol Dial Transplant, 25, pp.2218~2224 (2010)
69. Vasavada N, "Role of excess volume in the pathophysiology of hypertension in chronic kidney disease", Kidney Int, 64, pp.1772~1779 (2003)
70. Hansson L, "Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension : the Captopril Prevention Project(CAPPP)randomised trial", Lancet, 353, pp.611~616 (1999)
71. Hawkins RG, "Is population-wide diuretic use directly associated with the incidence of end-stage renal disease in the United States? : a hypothesis", Am J Hypertens, 18, pp.744~749 (2005)
72. Khan YH, "Progression and outcomes of non-dialysis dependent chronic kidney disease patients : a single center longitudinal follow-up study", Nephrol(Carlton), 22, pp.25~34 (2017)
73. Khan YH, "Outcomes of diuretic use in pre-dialysis CKD patients with moderate renal deterioration attending tertiary care referral center", Clin Exp Nephrol, 21, pp.1011~1023 (2017)
74. Rahman M, "Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic : a report from the antihypertensive and lipid-lowering treatment to Prevent Heart Attack Trial(ALLHAT)", Arch Intern Med, 165, pp.936~946 (2005)
75. Fitzpatrick JK, "Loop and thiazide diuretic use and risk of chronic kidney disease progression : a multicentre observational cohort study", BMJ Open, 12, pp.e048755~ (2022)
76. 김수진, "Evaluating a shared decision-making intervention regarding dialysis modality: development and validation of self-assessment items for patients with chronic kidney disease", Kidney Research and Clinical Practice, 41(2), pp.175~187 (2022), 대한신장학회[DOI]

관련 논문AI추천